Genome editing for rare diseases

A Pradhan, TV Kalin, VV Kalinichenko - Current stem cell reports, 2020 - Springer
Abstract Purpose of the Review Significant numbers of patients worldwide are affected by
various rare diseases, but the effective treatment options to these individuals are limited …

Improved CRISPR/Cas9 gene editing in primary human myoblasts using low confluency cultures on Matrigel

H Goullée, RL Taylor, ARR Forrest, NG Laing… - Skeletal Muscle, 2021 - Springer
Background CRISPR/Cas9 is an invaluable tool for studying cell biology and the
development of molecular therapies. However, delivery of CRISPR/Cas9 components into …

Therapeutic Genome Editing and In Vivo Delivery

AC Ramirez-Phillips, D Liu - The AAPS Journal, 2021 - Springer
Improvements in the understanding of human genetics and its roles in disease development
and prevention have led to an increased interest in therapeutic genome editing via the use …

Molecular Genetic Therapies in the Muscular Dystrophies

S Nicolau, KM Flanigan - Principles and Practice of the Muscular …, 2024 - Springer
The identification of the genes causing the most common muscular dystrophies over the past
few decades has allowed the design of new classes of targeted therapeutics. A number of …

In vivo genome engineering for the treatment of muscular dystrophies

M Kustermann, MJ Rok, RD Cohn, EA Ivakine - Current Stem Cell Reports, 2020 - Springer
Abstract Purpose of Review Muscular dystrophies (MDs) are a heterogeneous collection of
inherited disorders which cause progressive muscle loss and weakness/hypotonia. Owing to …